Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00002258 | A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia | PHASE1 | COMPLETED | - | — | — | - | - | Jun 24, 2005 | 1 | United States |
| Name | Type | Description |
|---|---|---|
| Interleukin-3 | DRUG | - |
Inclusion Criteria Patients must have: * HIV seropositivity by Western blot. * Advanced ARC or AIDS as defined by CDC. * Cytopenia defined as total peripheral leukocyte count of \< 3,000 cells/mm3 or platelet count of \< 100,000 cells/mm3 or serum hemoglobin \< 10 g/dl. * Anticipated life expectan...